Comparative Pharmacology
Head-to-head clinical analysis: CLONAZEPAM versus KLONOPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLONAZEPAM versus KLONOPIN.
CLONAZEPAM vs KLONOPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
0.5 mg orally three times daily; maximum 20 mg/day
0.5 mg orally three times daily; maximum 20 mg/day
None Documented
None Documented
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."